Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282079 | 0.69 | CA12 (0.42) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL540266 | 0.68 | TSHR (0.39) | CA12CA1CA2MAPT | |
| SCHEMBL2881930 | 0.68 | TSHR (0.44) | CA12CA1CA2 | |
| SCHEMBL29439671 | 0.68 | TSHR (0.39) | CA12CA1CA2MAPT | |
| SCHEMBL2547218 | 0.67 | TSHR (0.42) | — | |
| SCHEMBL14867039 | 0.65 | BRD4 (0.42) | KDM4E | |
| SCHEMBL30824616 | 0.64 | PARP1 (0.49) | — | |
| SCHEMBL29370549 | 0.63 | MAPT (0.50) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL27392334 | 0.63 | MAPT (0.50) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL18172 | 0.63 | MAPT (0.50) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102404-A1 | THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102404-A1 | THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOF | TSHR, TRHR, THRB | CA12 1435/4885CA1 1235/4885CA2 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.